Leiden Bio Science Park welcomes Eli Lilly, strengthening The Netherlands’ position in life sciences with a $3 billion facility.
Eli Lilly and Company announced plans to build a new $3 billion facility in Katwijk, the Netherlands, which will become part of the Leiden Bio Science Park ecosystem. This major project will expand Lilly’s capacity to produce innovative medicines and strengthen the company’s global supply chain.
Eli Lilly will bring 500 high-wage jobs to the park, including highly skilled engineers, scientists, operations personnel and lab technicians, who will leverage state-of-the-art technology to produce life-changing innovative medicines.
Beyond its economic impact, Lilly’s presence will also enrich our community by bringing expertise, fostering new collaborations and creating opportunities for knowledge exchange across academia, industry, and government.
“Leiden Bio Science Park offers access to a skilled workforce, reliable infrastructure and proven pharmaceutical manufacturing capabilities.” said David A. Ricks, Eli Lilly chair and CEO.
“I am truly proud that Eli Lilly has chosen the Netherlands, Katwijk and the Leiden Bio Science Park after considering many locations across Europe,” said Vincent Karremans, Minister of Economic Affairs of the Netherlands. “The arrival of Eli Lilly will not only bring new jobs and investments, but also boost collaboration in the field of innovative medicines, helping us work together on solutions that truly improve people’s health and lives.”
We are pleased to welcome Eli Lilly to the Leiden Bio Science Park, strengthening our position as a leading Life Sciences & Health hub in Europe, working on the future of health!
Their new facility in Katwijk will become part of our growing ecosystem, adding significant value to the entire life sciences value chain; from research and development to large-scale manufacturing. Red biotech and life sciences & health needs this end– to– end strategy. By keeping this value chain, in which knowledge, development and production come together, complete and strengthening it, we remain attractive for new investments, such as the arrival of this new production facility.
The arrival of this facility of Ei Lilly therefore confirms this end-to-end structure making Leiden an even more mature, internationally competitive ecosystem. Recent research by the European Patent Office also shows that the LUMC is a leader in technology transfer between science and the market – another fine example of the innovative power of the knowledge base and, together with today’s announcement, it also underlines how strongly Leiden contributes to solutions that actually reach patients and society and truly improve people’s health and lives.
To learn more, visit Lilly.com/news
From the Van Nelle Factory to BioPartner 5, from heritage to future, from start-up to innovative lab design agency. After an inspiring and innovative seven-year start at the...
Starting Friday, November 14 at 4:00 p.m., two temporary closures (in place for the duration of the Plesmanlaan project, until approximately Q3 2027) will be implemented for...
24 October 2025, Over the past 20 years, Dutch hospitals have filed 559 European patent applications. This emerges from a new study by the European Patent Office and Fraunhofer...